Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Rashid W, et al. Among authors: ford hl. Pract Neurol. 2024 Nov 11:pn-2024-004228. doi: 10.1136/pn-2024-004228. Online ahead of print. Pract Neurol. 2024. PMID: 39532459 Review.
Decarboxylative Cross-Coupling Enabled by Fe and Ni Metallaphotoredox Catalysis.
Nsouli R, Nayak S, Balakrishnan V, Lin JY, Chi BK, Ford HG, Tran AV, Guzei IA, Bacsa J, Armada NR, Zenov F, Weix DJ, Ackerman-Biegasiewicz LKG. Nsouli R, et al. Among authors: ford hg. J Am Chem Soc. 2024 Oct 30;146(43):29551-29559. doi: 10.1021/jacs.4c09621. Epub 2024 Oct 18. J Am Chem Soc. 2024. PMID: 39422549 Free PMC article.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: ford hl. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article. Clinical Trial.
916 results